"The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.
Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is"...
(Generic versions may still be available.)
DOSAGE AND ADMINISTRATION
The recommended dose of RAPTIVA (efalizumab) is a single 0.7 mg/kg SC conditioning dose followed by weekly SC doses of 1 mg/kg (maximum single dose not to exceed a total of 200 mg).
RAPTIVA (efalizumab) is intended for use under the guidance and supervision of a physician. If it is determined to be appropriate, patients may self-inject RAPTIVA (efalizumab) after proper training in the preparation and injection technique and with medical follow-up (see PRECAUTIONS: Information for Patients).
Preparation for Administration
RAPTIVA (efalizumab) should be administered using the sterile, disposable syringe and needles provided (see HOW SUPPLIED section). Remove the cap from the pre-filled syringe containing sterile water for injection (non-USP) and attach the needle to the syringe. Remove the plastic cap protecting the rubber stopper of the RAPTIVA (efalizumab) vial and wipe the top of the rubber stopper with one of the provided alcohol swabs. After cleaning with the alcohol swab, do not touch the top of the vial. To prepare the RAPTIVA (efalizumab) solution, using the provided pre-filled diluent syringe slowly inject the 1.3 mL of sterile water for injection (non-USP) into the RAPTIVA (efalizumab) vial. Swirl the vial with a GENTLE rotary motion to dissolve the product. DO NOT SHAKE. Shaking will cause foaming of the RAPTIVA (efalizumab) solution. Generally, dissolution of RAPTIVA (efalizumab) takes less than 5 minutes. RAPTIVA (efalizumab) is provided as a single-use vial and contains no antibacterial preservatives. Reconstitute immediately before use and use only once. If the reconstituted RAPTIVA (efalizumab) is not used immediately, store the RAPTIVA (efalizumab) vial at room temperature and use within 8 hours. The reconstituted solution should be clear to pale yellow and free of particulates.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to subcutaneous administration. If particulates or discolorations are noted, the product should not be used.
Insert the needle into the vial containing the RAPTIVA (efalizumab) solution, invert the vial, and keeping the needle below the level of the liquid, withdraw the dose to be given into the syringe. Replace the needle on the syringe with a new needle.
No other medications should be added to solutions containing RAPTIVA (efalizumab) , and RAPTIVA (efalizumab) should not be reconstituted with other diluents.
Following administration, discard any unused reconstituted RAPTIVA (efalizumab) solution.
Stability and Storage
Do not use a vial beyond the expiration date stamped on the carton or vial label. RAPTIVA (efalizumab) (lyophilized powder) must be refrigerated at 2-8°C (36-46°F). Protect the vial from exposure to light. Store in original carton until time of use.
RAPTIVA (efalizumab) is supplied as a lyophilized, sterile powder to deliver 125 mg of efalizumab per single-use vial.
Each RAPTIVA (efalizumab) carton contains four trays. Each tray contains one single-use vial designed to deliver 125 mg of efalizumab, one single-use prefilled diluent syringe containing 1.3 mL sterile water for injection (non-USP), two 25 gauge × 5/8 inch needles, two alcohol prep pads, a package insert with an accompanying patient information insert. The NDC number for the four administration dose pack carton is 50242-058-04.
Manufactured by: Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990. Revised: 3/13/09This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 4/16/2009
Additional Raptiva Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.